Amanote Research
Register
Sign In
Health State Utilities in Patients With Relapsing Remitting Multiple Sclerosis Treated With Cladribine Tablets
Value in Health
- United Kingdom
doi 10.1016/j.jval.2017.08.1961
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2017
Authors
SL Wong
Hohnhorst Pv
R Hettle
P Konings
Publisher
Elsevier BV
Related search
Cognitive Profile of Patients With Relapsing Remitting Multiple Sclerosis
Arquivos de Neuro-Psiquiatria
Biological Psychiatry
Neurology
Cost-Effectiveness of Cladribine Tablets, Alemtuzumab and Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis With High Disease Activity in England
Journal of Medical Economics
Health Policy
Progressive Gray Matter Damage in Patients With Relapsing-Remitting Multiple Sclerosis
Archives of Neurology
Pnd62 - Cost-Effectiveness of Cladribine Tablets in the Treatment of Patients With Highly Active Relapsing Multiple Sclerosis in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Work Participation and Executive Abilities in Patients With Relapsing-Remitting Multiple Sclerosis
PLoS ONE
Multidisciplinary
Cladribine for Highly Active Relapsing Multiple Sclerosis
Prescriber
Pharmacology
Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis
Neurotherapeutics
Neurology
Pharmacology
Treatment of Remitting-Relapsing Multiple Sclerosis (MS) With Cladribine: Results of an Open Pilot Study at 18 Months
Journal of Neurology
Neurology
Characteristics of Pediatric Patients With Relapsing Remitting Multiple Sclerosis Taking Disease Modifying Agents
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
